TABLE 2.
Univariate and multivariate analyses for PFS and OS
| PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95%CI) | p | HR (95%CI) | p | HR (95%CI) | p | HR (95%CI) | p | |
| IMWG frailty score, frail | 4.191 (1.504–11.680) | .006 | ‐ | ‐ | 3.536 (1.268–9.860) | .016 | ‐ | ‐ |
| Refractory to BTZ, yes | 5.025 (1.778–14.200) | .002 | 6.402 (1.880–21.800) | .003 | 4.330 (1.610–11.650) | .004 | 3.227 (1.074–9.700) | .037 |
| Refractory to LEN, yes | 4.135 (1.465–11.670) | .007 | 8.751 (2.273–33.690) | .002 | 2.447 (0.964–6.214) | .060 | 3.376 (1.159–9.829) | .026 |
| Serum LDH level, >ULN | 2.213 (0.606–8.087) | .230 | ‐ | ‐ | 4.328 (1.608–11.650) | .004 | ‐ | ‐ |
| Serum β2‐mG level, ≥5.5 mg/dl | 1.326 (0.466–3.771) | .597 | ‐ | ‐ | 6.035 (1.946–18.720) | .002 | 4.949 (1.520–16.110) | .008 |
| Serum albumin level, < 3.5 g/dl | 1.988 (0.718–5.508) | .149 | ‐ | ‐ | 2.993 (1.186–7.556) | .020 | ‐ | ‐ |
Abbreviations: BTZ, bortezomib; IMWG, international myeloma working group; LDH, lactate dehydrogenase; LEN, lenalidomide; ULN, upper limit of normal, β2‐mG, β2‐microglobulin.